Current Change: Seadrill Limited (NYSE: SDRL)

Seadrill Limited is part of the energy sector and is in the oil and gas drilling industry. The company CEO is Anton Dibowitz. Previous Intraday Performance:

The SDRL shares had a previous change of -2.27% which opened at 9.27 and closed at 9.06. It moved to an intraday high of 9.45 and a low of 8.91. Historical Performance:

Over the last five trading days, SDRL shares returned -7.36% and in the past 30 trading days it returned 3.90%. Over three months, it changed -4.83%. In one year it has changed 3,981.08% and within that year its 52-week high was 26.72 and its 52-week low was 0.10. SDRL stock is 8,960.00% above its 52 Week Low.

Our calculations result in a 200 day moving average of 14.89 and a 50 day moving average of 8.82. Right now, SDRL stock is trading -39.15% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down. Liquidity:

The company has a market cap of $906.0m with 100.0m shares outstanding and a float of 100.0m shares. Trading volume was 326,085 shares and has experienced an average volume of 539,248 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock . Earnings:

The last annual reported EPS for Seadrill Limited was -22.55 which ended on 31st of December 2018.

Base on our calculations, the intrinsic value per share is 17.06, which means it might be undervalued and has a margin of safety of 46.88%

The next earnings report will be: 05-02-2019

The growth of the EPS is critical in understanding the current valuation of Seadrill Limited; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 0.30% over the last twelve months. Indicators Also to Watch:

Based on the latest filings, there is 54.80% of institutional ownership. Short-interest was 6,142,162, which was 6.14% of shares outstanding. The short-interest ratio or days-to-cover ratio was 10.21. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

I calculated the beta to be 45.32

PR Newswire: Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -97.85%, return on assets is -31.95%, price-to-sales is 0.52 and price-to-book is 0.32. Company Score Card:

Results are out of six:
2 : Growth Expectations Result
1 : Financial Safety Result
0 : Past Performance Result
3 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result

Tags:, ,